Track PolyPid Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

PolyPid Ltd. PYPD Open PolyPid Ltd. in new tab

4.73 USD
EPS
-2.09
P/B
7.40
ROE
-366.29
Beta
1.41
Target Price
12.25 USD
PolyPid Ltd. logo

PolyPid Ltd.

🧾 Earnings Recap – Q3 2025

PolyPid Ltd. reported significant progress in Q3 2025, highlighted by a scheduled pre-NDA meeting with the FDA for DPLEX 100, a system aimed at preventing surgical site infections, positioning the company for key commercial milestones ahead.

  • Scheduled pre-NDA meeting with the FDA for DPLEX 100 in early December is a critical step towards market introduction.
  • Positive results from a new market access study indicate strong demand for DPLEX 100 among surgeons and hospital pharmacy directors.
  • Successful completion of GMP inspection supports the company’s manufacturing readiness for both the US and European markets.
  • Ongoing strategic discussions with potential US partners enhance the commercial outlook leveraging strong Phase III trial results.
  • PolyPid is advancing its pipeline, indicating future growth opportunities in oncology, obesity, and diabetes.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 12, 2026
EPS-2.09
Book Value0.60
Price to Book7.40
Debt/Equity25.48
% Insiders21.329%
Estimates
Forward P/E-4.66
Forward EPS-0.96
Target Mean Price12.25

DCF Valuation

Tweak assumptions to recompute fair value for PolyPid Ltd. (PYPD)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

PolyPid Ltd. Logo PolyPid Ltd. Analysis (PYPD)

Israel Health Care Official Website Stock

Is PolyPid Ltd. a good investment? PolyPid Ltd. (PYPD) is currently trading at 4.73 USD. Market analysts have a consensus price target of 12.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: PolyPid Ltd. is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -0.96.

Investor FAQ

Does PolyPid Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is PolyPid Ltd.?

PolyPid Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -2.09.

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Exchange Ticker
NGM (Sweden) PYPD

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Sept. 21, 2023 0.030000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion